DEF 14A: Oruka Therapeutics Seeks Stockholder Approval for Series A Preferred Stock Conversion at Special Meeting

Oruka Therapeutics is holding a special meeting on November 14, 2024, to seek stockholder approval for the conversion of its Series A Non-Voting Convertible Preferred Stock into common stock, as required by Nasdaq listing rules.

Summary

• Oruka Therapeutics, Inc. will hold a Special Meeting of Stockholders on November 14, 2024, to vote on two proposals.
• The primary proposal is to approve the issuance of common stock upon conversion of the company's Series A Non-Voting Convertible Preferred Stock, issued in September 2024, in accordance with Nasdaq Listing Rule 5635(d).
• The second proposal is to approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies.
• The Board of Directors has set October 16, 2024, as the Record Date for determining stockholders eligible to vote.
• The meeting will be held virtually at www.virtualshareholdermeeting.com/ORKA2024SM.
• On August 29, 2024, ARCA biopharma, Inc. completed a merger with Oruka Therapeutics Operating Company, LLC, and changed its name to Oruka Therapeutics, Inc. and ticker symbol to ORKA.
• The company entered into a Securities Purchase Agreement on September 11, 2024, for gross proceeds of approximately $200.5 million, involving the issuance of common stock, Series A Preferred Stock, and pre-funded warrants.
• If Proposal 1 is approved, each share of Series A Preferred Stock will automatically convert into 1,000 shares of common stock, subject to beneficial ownership limitations, resulting in 2,439,000 shares of common stock issuable upon conversion.
• A Registration Rights Agreement was also entered into, requiring the company to file a registration statement with the SEC by November 15, 2024, to register the resale of the common stock sold in the Private Placement, the shares of common stock issuable upon conversion of the Series A Preferred Stock sold in the Private Placement and shares issuable upon exercise of the pre-funded warrants sold in the Private Placement.
• The company is required to use commercially reasonable efforts to have the registration statement declared effective within 90 days thereafter, subject to certain exceptions.
• If stockholders do not approve the conversion, holders of the Series A Preferred Stock may require the company to settle their shares for cash at fair value, which could materially affect the company's results of operations.

Sentiment

Score: 7

Explanation: The document is primarily procedural, outlining the steps for a special meeting and seeking approval for a previously announced transaction. The sentiment is neutral to slightly positive, as the company is taking steps to strengthen its financial position and comply with regulatory requirements.

Positives

• Successful completion of a $200.5 million private placement strengthens the company's financial position.
• The virtual special meeting format expands stockholder access and improves communication.
• The Board of Directors recommends voting FOR the proposals.

Negatives

• The sale into the public market of the shares of common stock issuable upon conversion of the Series A Preferred Stock could materially and adversely affect the market price of our common stock.
• Failure to obtain stockholder approval for the conversion could lead to a cash settlement requirement, negatively impacting the company's financial results.
• The need to hold multiple stockholder meetings every 90 days until approval is obtained could be time-consuming and costly.

Risks

• The market price of Oruka's common stock could be negatively impacted by the sale of shares issued upon conversion of the Series A Preferred Stock.
• The company may face financial strain if forced to settle the Series A Preferred Stock for cash due to lack of stockholder approval.
• The company is subject to risks and uncertainties described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) on September 5, 2024 and other subsequent documents we file with the SEC.

Future Outlook

The company intends to file a registration statement with the SEC by November 15, 2024, and use commercially reasonable efforts to have it declared effective within 90 days, subject to certain exceptions.

Management Comments

• Lawrence Klein, Ph.D., President, Chief Executive Officer and Director, urges stockholders to vote as promptly as possible.
• The company believes the virtual meeting expands stockholder access, improves communications and lowers costs while reducing the environmental impact of the meeting.

Industry Context

The document relates to corporate governance procedures and compliance with Nasdaq listing rules, which are standard practices for publicly traded companies.

Comparison to Industry Standards

• Seeking stockholder approval for significant stock issuances is a common practice among publicly traded companies to comply with exchange listing rules and protect shareholder interests.
• Virtual stockholder meetings are increasingly adopted by companies to enhance accessibility and reduce costs, aligning with broader trends in corporate governance.
• The timelines for filing registration statements and seeking effectiveness are consistent with SEC regulations and industry norms.

Related Party Transactions

• Peter Harwin, a director of the Company and a managing member of Fairmount Funds Management LLC (Fairmount), has an interest in the matter as Fairmount Healthcare Fund II L.P. purchased shares of common stock and Series A Preferred Stock in the Private Placement.

Stakeholder Impact

• Approval of the proposals could impact shareholders through potential dilution and market price fluctuations.
• Failure to approve the proposals could impact the company's financial stability and operations.

Next Steps

• Stockholders to vote on the proposals at the Special Meeting on November 14, 2024.
• The company to file a registration statement with the SEC by November 15, 2024.
• The company to seek effectiveness of the registration statement within 90 days.

Key Dates

Keywords

Oruka Therapeutics, Special Meeting, Series A Preferred Stock, Stockholder Approval, Conversion, Private Placement, Nasdaq Listing Rule, Proxy Statement, Common Stock